Quality Isn’t Just a Checkbox — Can Better Workforce Skills Drive Lower Costs?

Healthcare quality isn’t improving at scale, despite advances in technology, because many systems treat it as another compliance task rather than a priority. Stephanie Mercado, CEO of the National Association for Healthcare Quality (NAHQ), argued that investing in workforce skills and standardizing roles can drive safer, higher-quality care while delivering measurable cost savings — as…

Read More

Big Bets, Long Bets: Investing in the Power of Ideas

With science funding catapulted into the cultural conversation more than ever in the last year, it faces a critical inflection point. There is an opportunity to design a path forward that builds stability in the short term and opens doors in the long term for foundational and transformational science and technology solutions that will benefit…

Read More

She Co-Founded the Office That Became DOGE. Now, She Sees ‘Irresponsible Transformation.’

Jennifer Pahlka is perhaps best known as the founder of Code for America, a widely respected nonprofit that helped formalize the principles of civic tech, a movement leveraging design and technology expertise to improve public access to government services and data. Notably, the organization reimagined the online application for California’s food assistance program, which once…

Read More

Médicos, callados mientras Florida busca terminar con décadas de mandatos de vacunación infantil

SARASOTA, Florida — Florida planea eliminar casi medio siglo de vacunas infantiles obligatorias contra enfermedades que han causado muertes y dejado secuelas en millones de niños. Muchos críticos, incluidos profesionales de salud, temen hablar públicamente en contra de esta decisión. Con el apoyo del gobernador republicano Ron DeSantis, Joseph Ladapo, cirujano general del estado, anunció…

Read More

Going In Reverse Is Faster Way Forward for Crescent Bio’s Cancer Immunotherapy

Crescent Biopharma is going public via a reverse merger with GlycoMimetics that will capitalize the combined company with $200 million. Crescent’s lead program is a bispecific antibody for cancer that replicates the properties of a Summit Therapeutics bispecific drug that recently trounced Merck’s blockbuster med Keytruda in a pivotal head-to-head study. The post Going In…

Read More